Increased aldosterone: Mechanism of hypertension in obesity

Seminars in Nephrology

Volumn 34, Issue 3, 2014, Pages 340-348

  Flynn, Colleen ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Aldosterone; Hypertension; Obesity

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ALISKIREN; AMILORIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; CATECHOL METHYLTRANSFERASE; CORTICOTROPIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; MINERALOCORTICOID RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TRIAMTERENE; ANTIHYPERTENSIVE AGENT;

ADIPOCYTE; ALDOSTERONE BLOOD LEVEL; ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE REGULATION; BODY MASS; CELL INFILTRATION; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; GASTRIC BANDING; GENETIC POLYMORPHISM; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HYPERTENSION; LIFESTYLE; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN POLYMORPHISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYSTOLIC BLOOD PRESSURE; WAIST HIP RATIO; WATER ABSORPTION; ZONA GLOMERULOSA; COMPLICATION; PHYSIOLOGY;

ALDOSTERONE; ANTIHYPERTENSIVE AGENTS; HUMANS; HYPERTENSION; OBESITY;

EID: 84904010578     PISSN: 02709295     EISSN: 15584488     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2014.04.009     Document Type: Review

References (74)

1. Flegal K.M., Carroll M.D., Ogden C.L., Curtin L.R. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010, 303:235-241.
2. Landsberg L., Aronne L.J., Beilin L.J., et al. Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment: a position paper of The Obesity Society and the American Society of Hypertension. J Clin Hypertens 2013, 15:14-33.
3. Stamler J., Dyer A.R., Shekelle R.B., Neaton J., Stamler R. Relationship of baseline major risk factors to coronary and all-cause mortality, and to longevity: findings from long-term follow-up of Chicago cohorts. Cardiology 1993, 82:191-222.
4. Kannel W.B., Brand N., Skinner J.J., Dawber T.R., McNamara P.M. The relation of adiposity to blood pressure and development of hypertension. The Framingham study. Ann Intern Med 1967, 67:48-59.
5. Lapidus L., Bengtsson C., Larsson B., Pennert K., Rybo E., Sjostrom L. Distribution of adipose tissue and risk of cardiovascular disease and death: a 12 year follow up of participants in the population study of women in Gothenburg, Sweden. Br Med J 1984, 289:1257-1261.
6. Larsson B., Svardsudd K., Welin L., Wilhelmsen L., Bjorntorp P., Tibblin G. Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year follow up of participants in the study of men born in 1913. Br Med J 1984, 288:1401-1404.
7. Masuo K., Mikami H., Ogihara T., Tuck M.L. Weight gain-induced blood pressure elevation. Hypertension 2000, 35:1135-1140.
8. Gentile C.L., Orr J.S., Davy B.M., Davy K.P. Cardiorespiratory fitness influences the blood pressure response to experimental weight gain. Obesity 2007, 15:3005-3012.
9. Israeli E., Schochat T., Korzets Z., Tekes-Manova D., Bernheim J., Golan E. Prehypertension and obesity in adolescents: a population study. Am J Hypertens 2006, 19:708-712.
10. Palatini P., Saladini F., Mos L., et al. Obesity is a strong determinant of hypertensive target organ damage in young-to-middle-age patients. Int J Obes (Lond) 2013, 37:224-229.
11. Lee S.K., Kim S.H., Cho G.Y., et al. Obesity phenotype and incident hypertension: a prospective community-based cohort study. J Hypertens 2013, 31:145-151.
12. Sjostrom L., Lindroos A.K., Peltonen M., et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004, 351:2683-2693.
13. Brethauer S.A., Aminian A., Romero-Talamas H., et al. Can diabetes be surgically cured? Long-term metabolic effects of bariatric surgery in obese patients with type 2 diabetes mellitus. Ann Surg 2013, 258:628-636. discussion 36-7.
14. Pontiroli A.E., Alberto M., Paganelli M., Saibene A., Busetto L. Metabolic syndrome, hypertension, and diabetes mellitus after gastric banding: the role of aging and of duration of obesity. Surg Obes Relat Dis 2013, 9:894-900.
15. Ferrannini E., Natali A., Capaldo B., Lehtovirta M., Jacob S., Yki-Jarvinen H. Insulin resistance, hyperinsulinemia, and blood pressure: role of age and obesity. European Group for the Study of Insulin Resistance (EGIR). Hypertension 1997, 30:1144-1149.
16. Hamdy O., Porramatikul S., Al-Ozairi E. Metabolic obesity: the paradox between visceral and subcutaneous fat. Curr Diabetes Rev 2006, 2:367-373.
17. Weisberg S.P., McCann D., Desai M., Rosenbaum M., Leibel R.L., Ferrante A.W. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003, 112:1796-1808.
18. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 2005, 115:911-919. quiz 20.
19. Buchwald H., Avidor Y., Braunwald E., et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004, 292:1724-1737.
20. Masuo K., Katsuya T., Fu Y., Rakugi H., Ogihara T., Tuck M.L. Beta2- and beta3-adrenergic receptor polymorphisms are related to the onset of weight gain and blood pressure elevation over 5 years. Circulation 2005, 111:3429-3434.
21. Xie T., Ho S.L., Ramsden D. Characterization and implications of estrogenic down-regulation of human catechol-O-methyltransferase gene transcription. Mol Pharmacol 1999, 56:31-38.
22. Lachman H.M., Papolos D.F., Saito T., Yu Y.M., Szumlanski C.L., Weinshilboum R.M. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 1996, 6:243-250.
23. Annerbrink K., Westberg L., Nilsson S., Rosmond R., Holm G., Eriksson E. Catechol O-methyltransferase val158-met polymorphism is associated with abdominal obesity and blood pressure in men. Metabolism 2008, 57:708-711.
24. Stefanski A., Majkowska L., Ciechanowicz A., et al. Association between the Pro12Ala variant of the peroxisome proliferator-activated receptor-gamma2 gene and increased 24-h diastolic blood pressure in obese patients with type II diabetes. J Human Hypertens 2006, 20:684-692.
25. Xanthakis V., Vasan R.S. Aldosterone and the risk of hypertension. Curr Hypertens Rep 2013, 15:102-107.
26. Newton-Cheh C., Guo C.Y., Gona P., et al. Clinical and genetic correlates of aldosterone-to-renin ratio and relations to blood pressure in a community sample. Hypertension 2007, 49:846-856.
27. Hattangady N.G., Olala L.O., Bollag W.B., Rainey W.E. Acute and chronic regulation of aldosterone production. Mol Cell Endocrinol 2012, 350:151-162.
28. Briet M., Schiffrin E.L. Vascular actions of aldosterone. J Vasc Res 2013, 50:89-99.
29. Shibata H., Itoh H. Mineralocorticoid receptor-associated hypertension and its organ damage: clinical relevance for resistant hypertension. Am J Hypertens 2012, 25:514-523.
30. Clark D., Ahmed M.I., Calhoun D.A. Resistant hypertension and aldosterone: an update. Can J Cardiol 2012, 28:318-325.
31. Strazzullo P., Iacone R., Iacoviello L., et al. Genetic variation in the renin-angiotensin system and abdominal adiposity in men: the Olivetti Prospective Heart Study. Ann Intern Med 2003, 138:17-23.
32. Kostis J.B., Wilson A.C., Hooper W.C., et al. Association of angiotensin-converting enzyme DD genotype with blood pressure sensitivity to weight loss. Am Heart J 2002, 144:625-629.
33. Goodfriend T.L. Obesity, sleep apnea, aldosterone, and hypertension. Curr Hypertens Rep 2008, 10:222-226.
34. Ruano M., Silvestre V., Castro R., et al. Morbid obesity, hypertensive disease and the renin-angiotensin-aldosterone axis. Obes Surg 2005, 15:670-676.
35. Licata G., Scaglione R., Ganguzza A., et al. Central obesity and hypertension. Relationship between fasting serum insulin, plasma renin activity, and diastolic blood pressure in young obese subjects. Am J Hypertens 1994, 7:314-320.
36. Dall'Asta C., Vedani P., Manunta P., et al. Effect of weight loss through laparoscopic gastric banding on blood pressure, plasma renin activity and aldosterone levels in morbid obesity. Nutr Metab Cardiovasc Dis 2009, 19:110-114.
37. Engeli S., Bohnke J., Gorzelniak K., et al. Weight loss and the renin-angiotensin-aldosterone system. Hypertension 2005, 45:356-362.
38. Licata G., Volpe M., Scaglione R., Rubattu S. Salt-regulating hormones in young normotensive obese subjects. Effects of saline load. Hypertension 1994, 23:I20-I24.
39. Goodfriend T.L., Egan B.M., Kelley D.E. Aldosterone in obesity. Endocr Res 1998, 24:789-796.
40. Ritchie S.A., Connell J.M. The link between abdominal obesity, metabolic syndrome and cardiovascular disease. Nutr Metab Cardiovasc Dis 2007, 17:319-326.
41. Fox C.S., Massaro J.M., Hoffmann U., et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation 2007, 116:39-48.
42. Vogt B., Bochud M., Burnier M. The association of aldosterone with obesity-related hypertension and the metabolic syndrome. Semin Nephrol 2007, 27:529-537.
43. Goodfriend T.L., Ball D.L., Egan B.M., Campbell W.B., Nithipatikom K. Epoxy-keto derivative of linoleic acid stimulates aldosterone secretion. Hypertension 2004, 43:358-363.
44. Ehrhart-Bornstein M., Lamounier-Zepter V., Schraven A., et al. Human adipocytes secrete mineralocorticoid-releasing factors. Proc Natl Acad Sci U S A 2003, 100:14211-14216.
45. Schinner S., Willenberg H.S., Krause D., et al. Adipocyte-derived products induce the transcription of the StAR promoter and stimulate aldosterone and cortisol secretion from adrenocortical cells through the Wnt-signaling pathway. Int J Obes (Lond) 2007, 31:864-870.
46. Engeli S., Gorzelniak K., Kreutz R., Runkel N., Distler A., Sharma A.M. Co-expression of renin-angiotensin system genes in human adipose tissue. J Hypertens 1999, 17:555-560.
47. Rondinone C.M., Rodbard D., Baker M.E. Aldosterone stimulated differentiation of mouse 3T3-L1 cells into adipocytes. Endocrinology 1993, 132:2421-2426.
48. Massiera F., Bloch-Faure M., Ceiler D., et al. Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASEB J 2001, 15:2727-2729.
49. Andrew R., Westerbacka J., Wahren J., Yki-Jarvinen H., Walker B.R. The contribution of visceral adipose tissue to splanchnic cortisol production in healthy humans. Diabetes 2005, 54:1364-1370.
50. Kannisto K., Pietilainen K.H., Ehrenborg E., et al. Overexpression of 11beta-hydroxysteroid dehydrogenase-1 in adipose tissue is associated with acquired obesity and features of insulin resistance: studies in young adult monozygotic twins. J Clin Endocrinol Metab 2004, 89:4414-4421.
51. Neter J.E., Stam B.E., Kok F.J., Grobbee D.E., Geleijnse J.M. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension 2003, 42:878-884.
52. Lloyd-Jones D.M., Liu K., Colangelo L.A., et al. Consistently stable or decreased body mass index in young adulthood and longitudinal changes in metabolic syndrome components: the Coronary Artery Risk Development in Young Adults Study. Circulation 2007, 115:1004-1011.
53. Dorresteijn J.A., Visseren F.L., Spiering W. Mechanisms linking obesity to hypertension. Obes Rev 2012, 13:17-26.
54. Wenzel U.O., Benndorf R., Lange S. Treatment of arterial hypertension in obese patients. Semin Nephrol 2013, 33:66-74.
55. Clark D., Guichard J.L., Calhoun D.A., Ahmed M.I. Recent advancements in the treatment of resistant hypertension. Postgrad Med 2012, 124:67-73.
56. Chapman N., Dobson J., Wilson S., et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007, 49:839-845.
57. Sharabi Y., Adler E., Shamis A., Nussinovitch N., Markovitz A., Grossman E. Efficacy of add-on aldosterone receptor blocker in uncontrolled hypertension. Am J Hypertens 2006, 19:750-755.
58. Ouzan J., Perault C., Lincoff A.M., Carre E., Mertes M. The role of spironolactone in the treatment of patients with refractory hypertension. Am J Hypertens 2002, 15:333-339.
59. Saha C., Eckert G.J., Ambrosius W.T., et al. Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension. Hypertension 2005, 46:481-487.
60. Wenzel U.O. Angiotensin-converting enzyme inhibitors and progression of renal disease: evidence from clinical studies. Contrib Nephrol 2001, 135:200-211.
61. Scheen A.J. Prevention of type 2 diabetes mellitus through inhibition of the renin-angiotensin system. Drugs 2004, 64:2537-2565.
62. Sharma A.M., Pischon T., Engeli S., Scholze J. Choice of drug treatment for obesity-related hypertension: where is the evidence?. J Hypertens 2001, 19:667-674.
63. Zanella M.T., Kohlmann O., Ribeiro A.B. Treatment of obesity hypertension and diabetes syndrome. Hypertension 2001, 38:705-708.
64. Dahlof B., Devereux R.B., Kjeldsen S.E., et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:995-1003.
65. Brenner B.M., Cooper M.E., de Zeeuw D., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861-869.
66. Muller D.N., Luft F.C. Direct renin inhibition with aliskiren in hypertension and target organ damage. Clin J Am Soc Nephrol 2006, 1:221-228.
67. Boschmann M., Nussberger J., Engeli S., et al. Aliskiren penetrates adipose and skeletal muscle tissue and reduces renin-angiotensin system activity in obese hypertensive patients. J Hypertens 2012, 30:561-566.
68. McMurray J.J., Abraham W.T., Dickstein K., Kober L., Massie B.M., Krum H.Aliskiren ALTITUDE, and the implications for ATMOSPHERE. Eur J Heart Fail 2012, 14:341-343.
69. Steckelings U.M., Paulis L., Namsolleck P., Unger T. AT2 receptor agonists: hypertension and beyond. Curr Opin Nephrol Hypertens 2012, 21:142-146.
70. Frohlich E.D. Clinical management of the obese hypertensive patient. Cardiol Rev 2002, 10:127-138.
71. Milliez P., Girerd X., Plouin P.F., Blacher J., Safar M.E., Mourad J.J. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005, 45:1243-1248.
72. Kisaka T., Ozono R., Ishida T., Higashi Y., Oshima T., Kihara Y. Association of elevated plasma aldosterone-to-renin ratio with future cardiovascular events in patients with essential hypertension. J Hypertens 2012, 30:2322-2330.
73. Horvath K., Jeitler K., Siering U., et al. Long-term effects of weight-reducing interventions in hypertensive patients: systematic review and meta-analysis. Arch Intern Med 2008, 168:571-580.
74. Stevens V.J., Obarzanek E., Cook N.R., et al. Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, phase II. Ann Intern Med 2001, 134:1-11.